Editorials

Drugs for cancer and copayments

BMJ 2008; 337 doi: http://dx.doi.org/10.1136/bmj.a527 (Published 30 June 2008) Cite this as: BMJ 2008;337:a527
  1. Ilora Finlay, independent crossbench member of House of Lords and professor of palliative medicine12,
  2. Nigel Crisp, independent crossbench member of House of Lords and honorary professor 13
  1. 1House of Lords, Westminster, London SW1A 0PW
  2. 2Cardiff University, Cardiff CF10 3AT
  3. 3London School of Hygiene and Tropical Medicine, London WC1E 7HT
  1. finlayi{at}parliament.uk

    Principles underpinning copayments must preserve equity, be transparent, and enhance knowledge on treatment outcomes

    The topic of how to pay for new and experimental drugs will not go away. The government of the United Kingdom has announced a review of whether patients should be able to remain NHS patients if they pay privately for such drugs. The current controversy exposes broader challenges, including how widely patients should make additional copayments for NHS services, and how an “episode of care” should be consistently defined.

    The NHS has changed radically since its foundation in 1948. Major breakthroughs in therapeutic drugs and applied technologies have offered new hope of prolonging life and improving quality of life in people with serious disease. Although drugs for cancer have hit the headlines, others that may have wider indications and applications are just around the corner. So should the NHS simply allow copayments to deal with the problem?

    In reality, other health systems signal problems with this.Copayments mean that—contrary to the founding principles of the NHS—access to treatment depends …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe